Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aimmune to Present at RBC Capital Markets Global Healthcare Conference

May 16, 2019

BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019--

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019, at 2:35 p.m. E.T. in New York City.

A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at  www.aimmune.com. A replay will also be available following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s C haracterized O ral D esensitization I mmuno T herapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product, AR101, is being developed as a treatment to reduce the frequency and severity and adverse events, including anaphylaxis, following exposure to peanut. The BLA for AR101 is under review by the FDA, which in 2015 granted AR101 Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4 to 17 years of age. Aimmune expects to file for marketing approval of AR101 in Europe in mid-2019. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see www.aimmune.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005267/en/

CONTACT: Investors:

Eric Bjerkholt

(650) 376-5582 or



Jerica Pitts

(312) 858-3469 or




SOURCE: Aimmune Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 05/16/2019 08:30 AM/DISC: 05/16/2019 08:30 AM


All contents © copyright 2019 The Associated Press. All rights reserved.